Ezetimibe and Pitavastatin Interaction

Synergistic
Researched 95% confidence

Ezetimibe and Pitavastatin have a synergistic interaction with 95% confidence. Pitavastatin and ezetimibe act on complementary cholesterol pathways — pitavastatin inhibits hepatic synthesis while ezetimibe blocks intestinal absorption. The combination provides an additional 15-20% LDL reduction beyond pitavastatin monotherapy. This pairing preserves pitavastatin's low interaction profile since ezetimibe is also minimally metabolized by CYP enzymes. Particularly useful for AAS users who need greater LDL reduction without switching to a higher-interaction statin. Both compounds affect the heart, so monitoring these systems is recommended.

Compound Profiles

Ezetimibe

Cholesterol Absorption Inhibitor | Lipid Management On Cycle

Ezetimibe selectively inhibits the NPC1L1 transporter protein located on the luminal surface of enterocytes in the jejunum of the small intestine. NPC1L1 is the critical gateway for intestinal cholesterol absorption, responsible for uptaking both dietary cholesterol and the much larger pool of biliary cholesterol that is recirculated through the enterohepatic cycle.

Half-life: ~22 hours Typical dose: 10 mg/day cardiovascular
npc1l1 hepatotoxiclipid disruptingteratogenic
View full profile

Pitavastatin

HMG-CoA Reductase Inhibitor | Low-Interaction Statin

Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for cholesterol biosynthesis in the liver. By blocking this enzyme, pitavastatin reduces intracellular cholesterol concentration in hepatocytes, triggering compensatory upregulation of LDL receptor expression on the hepatocyte surface.

Half-life: ~12 hours Typical dose: 1-4 mg/day cardiovascular
aromatase aromatase inhibitorhepatotoxiclipid disruptingteratogenic
View full profile

Combined Organ Load

Heart
low

Shared Safety Flags

2x 2 hepatotoxic compounds (Ezetimibe, Pitavastatin). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds disrupt lipids (Ezetimibe, Pitavastatin). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (Ezetimibe, Pitavastatin). Monitor accordingly.

Frequently Asked Questions

Can I take Ezetimibe with Pitavastatin?

Yes, Ezetimibe and Pitavastatin can generally be taken together. Pitavastatin and ezetimibe act on complementary cholesterol pathways — pitavastatin inhibits hepatic synthesis while ezetimibe blocks intestinal absorption. The combination provides an additional 15-20% LDL reduction beyond pitavastatin monotherapy. This pairing preserves pitavastatin's low interaction profile since ezetimibe is also minimally metabolized by CYP enzymes. Particularly useful for AAS users who need greater LDL reduction without switching to a higher-interaction statin.

Is Ezetimibe and Pitavastatin safe together?

Based on documented research, this combination is considered synergistic. However, shared safety flags include: hepatotoxic, lipid disrupting, teratogenic. Monitor accordingly.

What are the interactions between Ezetimibe and Pitavastatin?

Pitavastatin and ezetimibe act on complementary cholesterol pathways — pitavastatin inhibits hepatic synthesis while ezetimibe blocks intestinal absorption. The combination provides an additional 15-20% LDL reduction beyond pitavastatin monotherapy. This pairing preserves pitavastatin's low interaction profile since ezetimibe is also minimally metabolized by CYP enzymes. Particularly useful for AAS users who need greater LDL reduction without switching to a higher-interaction statin. This assessment has 95% confidence and is based on documented research data.

How should I time Ezetimibe and Pitavastatin?

Ezetimibe has a half-life of ~22 hours and Pitavastatin has a half-life of ~12 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Ezetimibe vs Pitavastatin

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.